BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) +/- chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)

by on 16 de maig de 2022 with No hi ha comentaris
  • Kopetz, S., Grothey, A., Yaeger, R., Ciardiello, F., Desai, J., Kim, T. W., . . . Tabernero, J. (2022). BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) +/- chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 40(4), TPS211. https://doi.org/10.1200/JCO.2022.40.4_suppl.TPS211 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *